Faculty Bibliography

The Geneva-based UN agency expressed optimism last week after convening a panel of 50 experts from 15 countries to review reports on a number of candidate vaccines for SARS, or severe acute respiratory syndrome. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic this year. [Marie-Paule Kieny] said that for many reasons it was too difficult to predict which research team would inject the first human with a SARS vaccine, and when, if ever, a vaccine might be available

The Geneva-based U.N. agency expressed optimism after convening a panel of 50 experts from 15 countries to review reports on a number of candidate SARS vaccines. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic earlier this year. [Marie-Paule Kieny] said in a telephone interview that it was too difficult to predict which research team would inject the first human with a SARS vaccine, and when, if ever, a vaccine might be available

The Geneva-based U.N. agency expressed optimism after convening a panel of 50 experts from 15 countries to review reports on a number of candidate SARS vaccines. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic earlier this year. [Marie-Paule Kieny] said in a telephone interview that it was too difficult to predict which research team would inject the first human with a SARS vaccine, and when, if ever, a vaccine might be available. Members of [Anthony S. Fauci]'s institute, a federal agency in Bethesda, Md., participated in the WHO panel meeting. In a telephone interview, Fauci said he shared the belief that clinical tests of a SARS vaccine could begin early next year

In another experiment with mice, the scientists documented the strength of the mouse antibody protection against SARS. The scientists took the portion of blood that contains antibodies, injected it into the mice and then deliberately exposed the animals to the SARS virus. That process, known as passive transfer of antibody, completely protected against reinfection, Dr. [Anthony S. Fauci] said. Dr. [Brian Murphy] has not developed an experimental SARS vaccine but the neutralizing antibody he found in his experiments provide an important measure for determining the effectiveness of experimental SARS vaccines, Dr. Fauci said. If SARS does not return, and an experimental vaccine is found safe and able to produce antibodies in humans, ethics would preclude deliberately trying to infect a vaccine recipient with the SARS virus as a scientific challenge. The reason is the high death rate from SARS, about 11 percent

The Geneva-based U.N. agency expressed optimism after convening a panel of 50 experts from 15 countries to review reports on a number of candidate vaccines for SARS, or severe acute respiratory syndrome. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic earlier this year

The Geneva-based U.N. agency expressed optimism after convening a panel of 50 experts from 15 countries to review reports on a number of candidate SARS vaccines. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic earlier this year. [Marie-Paule Kieny] said in a telephone interview that for many reasons it was too difficult to predict which research team would inject the first human with a SARS vaccine, and when, if ever, a vaccine might be available. There is no way now to know whether SARS will return, but if it surfaces this winter, a vaccine will not be available. As health officials prepare for another epidemic, they caution that all they can do is impose the stringent infection control measures that worked earlier this year. The measures include rapidly identifying and isolating patients; tracing all of their human contacts; quarantining many of them; having hospital workers use strict infection control measures like wearing masks, gowns and gloves; and international travel alerts

The first human tests of an experimental SARS vaccine could begin as early as January, with laboratory researchers making surprisingly rapid progress toward preventing the respiratory illness, the World Health Organization and a top U.S. health official say. The U.N. agency expressed optimism after convening 50 experts from 15 countries to review reports on a number of candidate SARS vaccines. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic earlier this year

The Geneva-based U.N. agency expressed optimism after convening a panel of 50 experts from 15 countries to review reports on a number of candidate SARS vaccines. Scientists in Canada, China, the United States and possibly other countries began developing them after the SARS epidemic earlier this year